EX-99.1 2 ea145166ex99-1_sapiens.htm PRESS RELEASE

Exhibit 99.1

 

 

Sapiens Reports Second Quarter 2021 Financial Results

 

Holon, Israel, August 4, 2021 – Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced its financial results for the second quarter ended June 30, 2021.

 

Summary Results for Second Quarter 2021 (USD in millions, except per share data)

 

   GAAP       Non-GAAP     
   June 30,
2021
   June 30,
2020
   % Change   June 30,
2021
   June 30,
2020
   % Change 
Revenue  $114.4   $93.1    22.9%  $115.0   $93.1    23.6%
Gross Profit  $46.6   $38.3    21.9%  $51.7   $41.9    23.4%
Gross Margin   40.8%   41.1%   (30) bps    45.0%   45.0%   - 
Operating Income  $13.2   $12.4    6.2%  $19.8   $16.8    17.9%
Operating Margin   11.5%   13.3%   (180) bps    17.2%   18.0%   (80) bps 
Net Income (*)  $10.4   $9.3    11.9%  $16.0   $13.3    19.7%
Diluted EPS  $0.19   $0.18    5.6%  $0.29   $0.26    11.5%

 

(*)Attributable to Sapiens’ shareholders.

 

“Sapiens second quarter results demonstrate the success of our strategy, as we continue to expand our global market presence in both P&C and L&A, and provide insurers of all tiers the broadest product portfolio and services offering in the market. This unique value proposition enables insurers to benefit from our pre-integrated, cloud-first, low-code “insurance-in-a-box” approach across the majority of our products, empowering them to choose between deploying our end-to-end solution, or any combination of its components, to meet their evolving needs,” stated Roni Al-Dor, President and CEO of Sapiens.

 

“In the second quarter Sapiens delivered a strong, year-over-year non-GAAP revenue growth of 24%, reaching a record high of $115 million. Non-GAAP operating margin reached 17.2%. In North America, we continue to make progress and have achieved sequential growth, as we execute our plan to continue to enhance our delivery capabilities. In Europe, we have been winning new business and have successfully completed new transformation projects, including with Tier-1 carriers. The Rest-of-the-World, which includes APAC and South Africa, continues on a path of growth. We are leveraging our global presence and rich product portfolio to further increase market share,” continued Mr. Al-Dor.

 

1

 

 

“We are increasing our 2021 revenue guidance for the second time. The new revenue guidance ranges from $461 to $466 million. We are also increasing our operating margin guidance to a range of 17.2% to 17.5%. Our strong performance reflects the important role Sapiens plays in our customers’ lifecycle and transformation journeys in the growing and evolving insurance industry.”

 

Quarterly Results Conference Call

 

Management will host a conference call and webcast today, August 4, 2021 at 9:30 a.m. Eastern Time (4:30 p.m. in Israel) to review and discuss Sapiens’ results.

 

Please call the following numbers (at least 10 minutes before the scheduled time) to participate:

 

North America (toll-free): + 1-888-642-5032; International: +972-3-918-0609; UK: 0-800-917-5108

 

The live webcast of the call can be viewed on Sapiens’ website at: https://www.sapiens.com/investor-relations/ir-events-presentations. A replay of the call will be available one business day following the completion of the event, at the same link for 90 days.

 

Non-GAAP Financial Measures

 

This press release contains the following non-GAAP financial measures: non-GAAP revenue, non-GAAP gross profit, non-GAAP operating income, non-GAAP net income attributed to Sapiens shareholders, non-GAAP basic and diluted earnings per share, Adjusted EBITDA and Adjusted Free Cash-Flow.

 

Sapiens believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Sapiens’ financial condition and results of operations. The Company’s management uses these non-GAAP measures to compare the Company’s performance to that of prior periods for trend analyses, for purposes of determining executive and senior management incentive compensation and for budgeting and planning purposes. These measures are used in financial reports prepared for management and in quarterly financial reports presented to the Company’s board of directors. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing the Company’s financial measures with other software companies, many of which present similar non-GAAP financial measures to investors.

 

2

 

 

Non-GAAP financial measures consist of GAAP financial measures adjusted to exclude: Valuation adjustment on acquired deferred revenue, amortization of capitalized software development and other intangible assets, capitalization of software development, stock-based compensation, compensation related to acquisition and acquisition-related costs, restructuring and cost reduction costs, and tax adjustments related to non-GAAP adjustments.

 

Management of the Company does not consider these non-GAAP measures in isolation, or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations, as they reflect the exercise of judgment by management about which expenses and income are excluded or included in determining these non-GAAP financial measures.

 

To compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. Sapiens urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate the Company’s business.

 

Reconciliation tables of the most comparable GAAP financial measures to the non-GAAP financial measures used in this press release are included with the financial tables of this release.

 

The Company defines Adjusted EBITDA as net profit, adjusted for valuation adjustment on acquired deferred revenue, stock-based compensation expense, depreciation and amortization, capitalized of software development costs, compensation expenses related to acquisition and acquisition-related costs, restructuring and cost reduction costs, financial expense (income), provision for income taxes and other income (expenses). These amounts are often excluded by other companies to help investors understand the operational performance of their business.

 

The Company uses Adjusted EBITDA as a measurement of its operating performance, because it assists in comparing the operating performance on a consistent basis by removing the impact of certain non-cash and non-operating items. Adjusted EBITDA reflects an additional way of viewing aspects of the operations that the Company believes, when viewed with the GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting its business. The Company uses Adjusted Free Cash-Flow as a measurement of its operating performance, and reconciles cash-flow from operating activities to Adjusted Free Cash-Flow, while reducing the amounts for capitalization of software development costs and capital expenditures. The Company adds back cash payments made for former acquisitions in respect of  future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, which were included in the cash-flow from operating activities. We believe that Adjusted Free Cash-Flow is useful in evaluating our business, because Adjusted Free Cash-Flow reflects the cash surplus available to fund the expansion of our business.

 

About Sapiens

 

Sapiens International Corporation empowers insurers to succeed in an evolving industry. The company offers digital software platforms, solutions and services for the property and casualty, life, pension and annuity, reinsurance, financial and compliance, workers’ compensation and financial markets. With more than 35 years of experience delivering to more than 600 organizations globally, Sapiens has a proven ability to satisfy customers’ core, data and digital requirements. For more information: www.sapiens.com.

 

Investors and Media Contact

 

Sapiens

Daphna Golden

Vice President, Head of Investor Relations

Email: ir@sapiens.com

 

Hayden IR
Brett Mass
Managing Partner
Phone: +1 646-536-7331
Email: Brett.Maas@HaydenIR.com

 

3

 

 

Forward Looking Statements

 

Certain matters discussed in this press release that are incorporated herein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to pandemic risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus pandemic, which adversely affected our results of operations, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company.

 

While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

 

4

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

U.S. dollars in thousands (except per share amounts)

 

   Three months ended   Six months ended 
   June 30   June 30 
   2021   2020   2021   2020 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
                 
Revenue   114,406    93,063    223,998    183,597 
Cost of revenue   67,782    54,804    133,118    109,074 
                     
Gross profit   46,624    38,259    90,880    74,523 
                     
Operating expenses:                    
Research and development, net   13,267    9,328    26,355    19,854 
Selling, marketing, general and administrative   20,183    16,528    38,986    31,988 
Total operating expenses   33,450    25,856    65,341    51,842 
                     
Operating income   13,174    12,403    25,539    22,681 
                     
Financial and other expenses, net   69    63    584    1,550 
Taxes on income   2,688    3,010    4,637    4,911 
                     
Net income   10,417    9,330    20,318    16,220 
                     
Attributable to non-controlling interest   13    33    80    103 
                     
Net income attributable to Sapiens’ shareholders   10,404    9,297    20,238    16,117 
                     
Basic earnings per share   0.19    0.19    0.37    0.32 
                     
Diluted earnings per share   0.19    0.18    0.36    0.32 
                     
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)   54,754    50,297    54,722    50,236 
                     
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)   55,548    51,173    55,558    51,128 

 

5

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED NON-GAAP STATEMENTS OF INCOME

U.S. dollars in thousands (except per share amounts)

 

    Three months ended     Six months ended  
    June 30     June 30  
    2021     2020     2021     2020  
    (unaudited)     (unaudited)     (unaudited)     (unaudited)  
                         
Revenue     115,036       93,063       225,258       183,597  
Cost of revenue     63,316       51,163       124,309       101,906  
                                 
Gross profit     51,720       41,900       100,949       81,691  
                                 
Operating expenses:                                
Research and development, net     15,226       10,579       29,946       22,542  
Selling, marketing, general and administrative     16,699       14,538       32,208       27,752  
Total operating expenses     31,925       25,117       62,154       50,294  
                                 
Operating income     19,795       16,783       38,795       31,397  
                                 
Financial and other expenses, net     69       63       584       1,550  
Taxes on income     3,738       3,347       7,249       5,992  
                                 
Net income     15,988       13,373       30,962       23,855  
                                 
Attributable to non-controlling interest     13       33       80       103  
                                 
Net income attributable to Sapiens’ shareholders     15,975       13,340       30,882       23,752  
                                 
Basic earnings per share     0.29       0.27       0.56       0.47  
                                 
Diluted earnings per share     0.29       0.26       0.56       0.46  
                                 
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)     54,754       50,297       54,722       50,236  
                                 
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)     55,548       51,173       55,558       51,128  

 

6

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND SUBSIDIARIES

 

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

U.S. dollars in thousands (except per share amounts)

 

   Three months ended   Six months ended 
   June 30,   June 30, 
   2021   2020   2021   2020 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
                 
GAAP revenue  114,406   93,063   223,998   183,597 
Valuation adjustment on acquired deferred revenue  630   -   1,260   - 
Non-GAAP revenue  115,036   93,063   225,258   183,597 
                 
GAAP gross profit   46,624    38,259    90,880    74,523 
Revenue adjustment   630    -    1,260    - 
Amortization of capitalized software   1,891    1,531    3,675    3,027 
Amortization of other intangible assets   2,575    2,110    5,134    4,141 
Non-GAAP gross profit   51,720    41,900    100,949    81,691 
                     
GAAP operating income   13,174    12,403    25,539    22,681 
Gross profit adjustments   5,096    3,641    10,069    7,168 
Capitalization of software development   (1,959)   (1,251)   (3,591)   (2,688)
Amortization of other intangible assets   1,358    698    2,724    1,287 
Stock-based compensation   1,471    764    2,870    1,386 
Acquisition-related costs *)   655    528    1,184    1,563 
Non-GAAP operating income   19,795    16,783    38,795    31,397 
                     
GAAP net income attributable to Sapiens’ shareholders   10,404    9,297    20,238    16,117 
Operating income adjustments   6,621    4,380    13,256    8,716 
Taxes on income   (1,050)   (337)   (2,612)   (1,081)
Non-GAAP net income attributable to Sapiens’ shareholders   15,975    13,340    30,882    23,752 

 

(*)Acquisition-related costs pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

 

7

 

 

Summary of NON-GAAP Financial Information
U.S. dollars in thousands (except per share amounts)

 

   Q2 2021   Q1 2021   Q4 2020   Q3 2020   Q2 2020 
                     
Revenues   115,036    110,222    102,936    97,968    93,063 
Gross profit   51,720    49,229    47,044    44,206    41,900 
Operating income   19,795    19,000    18,666    17,859    16,783 
Net income to Sapiens’ shareholders   15,975    14,908    14,461    13,746    13,340 
Adjusted EBITDA   20,920    20,120    20,032    19,010    17,854 
                          
Basic earnings per share   0.29    0.27    0.27    0.27    0.27 
Diluted earnings per share   0.29    0.27    0.27    0.27    0.26 

 

Non-GAAP Revenues by Geographic Breakdown
U.S. dollars in thousands

 

   Q2 2021   Q1 2021   Q4 2020   Q3 2020   Q2 2020 
                     
North America   46,767    44,754    47,303    49,979    46,610 
Europe   59,718    57,642    49,225    42,394    41,030 
Rest of the world   8,551    7,826    6,408    5,595    5,423 
                          
Total   115,036    110,222    102,936    97,968    93,063 

 

Adjusted Free Cash-Flow
U.S. dollars in thousands

 

   Q2 2021   Q1 2021   Q4 2020   Q3 2020   Q2 2020 
                     
Cash-flow from operating activities   26,845    11,755    21,030    16,705    14,761 
Increase in capitalized software development costs   (1,959)   (1,632)   (1,604)   (1,506)   (1,251)
Capital expenditures   (1,082)   (821)   (725)   (963)   (393)
Free cash-flow   23,804    9,302    18,701    14,236    13,117 
                          
Cash payments attributed to acquisition-related costs(*) (**)   -    1,280    2,363    242    1,562 
                          
Adjusted free cash-flow   23,804    10,582    21,064    14,478    14,679 

 

(*)Included in cash-flow from operating activities

 

(**)Acquisition-related payments pertain to payments on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

 

8

 

 

Adjusted EBITDA Calculation
U.S. dollars in thousands

 

   Three months ended   Six months ended 
   June 30   June 30 
   2021   2020   2021   2020 
                 
GAAP operating profit   13,174    12,403    25,539    22,681 
                     
Non-GAAP adjustments:                    
Valuation adjustment on acquired deferred revenue   630    -    1,260    - 
Amortization of capitalized software   1,891    1,531    3,675    3,027 
Amortization of other intangible assets   3,933    2,808    7,858    5,428 
Capitalization of software development   (1,959)   (1,251)   (3,591)   (2,688)
Stock-based compensation   1,471    764    2,870    1,386 
Compensation related to acquisition and acquisition-related costs   655    528    1,184    1,563 
                     
Non-GAAP operating profit   19,795    16,783    38,795    31,397 
                     
Depreciation   1,125    1,071    2,245    2,182 
                     
Adjusted EBITDA   20,920    17,854    41,040    33,579 

 

9

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

 

   June 30,   December 31, 
   2021   2020 
   (unaudited)   (unaudited) 
         
ASSETS        
         
CURRENT ASSETS        
Cash and cash equivalents   155,805    152,561 
Short-term bank deposit   20,000    30,000 
Trade receivables, net and unbilled receivables   70,214    65,409 
Other receivables and prepaid expenses   15,842    19,388 
           
Total current assets   261,861    267,358 
           
LONG-TERM ASSETS          
Property and equipment, net   15,640    16,970 
Severance pay fund   6,733    6,582 
Goodwill and intangible assets, net   352,224    363,597 
Operating lease right-of-use assets   49,777    54,390 
Other long-term assets   8,269    5,264 
           
Total long-term assets   432,643    446,803 
           
TOTAL ASSETS   694,504    714,161 
           
LIABILITIES AND EQUITY          
           
CURRENT LIABILITIES          
Trade payables   6,762    5,389 
Current maturities of Series B Debentures   19,796    19,796 
Accrued expenses and other liabilities   73,003    75,119 
Current maturities of operating lease liabilities   11,790    9,924 
Deferred revenue   42,573    34,548 
           
Total current liabilities   153,924    144,776 
           
LONG-TERM LIABILITIES          
Series B Debentures, net of current maturities   78,935    98,676 
Deferred tax liabilities   13,872    16,010 
Other long-term liabilities   12,847    12,129 
Long-term operating lease liabilities   43,586    48,773 
Redeemable non-controlling interest   483    517 
Accrued severance pay   9,676    9,586 
           
Total long-term liabilities   159,399    185,691 
           
EQUITY   381,181    383,694 
           
TOTAL LIABILITIES AND EQUITY   694,504    714,161 

 

10

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF CASH FLOW
U.S. dollars in thousands

 

   For the six months ended
June 30,
 
   2021   2020 
   (unaudited)   (unaudited) 

Cash flows from operating activities:

        
Net income   20,318    16,220 
Reconciliation of net income to net cash provided by operating activities:          
Depreciation and amortization   13,778    10,637 
Accretion of discount on Series B Debentures   55    77 
Capital loss from sale of property and equipment   36    - 
Stock-based compensation related to options issued to employees   2,870    1,386 
           
Net changes in operating assets and liabilities, net of amount acquired:          
Trade receivables, net and unbilled receivables   (8,655)   (11,554)
Deferred tax assets, net   (2,822)   (1,146)
Other operating assets   9,453    3,286 
Trade payables   1,230    (275)
Other operating liabilities   (5,449)   (2,187)
Deferred revenues   7,682    4,008 
Accrued severance pay, net   104    68 
           
Net cash provided by operating activities   38,600    20,520 
           
Cash flows from investing activities:          
Purchase of property and equipment   (1,903)   (945)
Withdrawal of (investment in) deposit   10,000    (379)
Proceeds from sale of property and equipment   1,011    - 
Proceeds from restricted deposit used for completed acquisition   -    22,890 
Proceeds from (payments for) business acquisitions, net of cash acquired   831    (22,483)
Capitalized software development costs   (3,591)   (2,688)
           
Net cash provided by (used in) investing activities   6,348    (3,605)
           
Cash flows from financing activities:          
Proceeds from employee stock options exercised   659    2,334 
Distribution of dividend   (20,253)   (6,632)
Repayment of Series B Debenture   (19,796)   (9,898)
Issuance of Series B Debentures, net of issuance expenses of $863   -    60,155 
Receipt of short-term loan   -    20,000 
Repayment of loan   -    (20,000)
Payment of contingent considerations   (537)   (538)
Dividend to non-controlling interest   (31)   - 
           
Net cash provided by (used in) financing activities   (39,958)   45,421 
           
Effect of exchange rate changes on cash and cash equivalents   (1,746)   (652)
           
Increase in cash and cash equivalents   3,244    61,684 
Cash and cash equivalents at the beginning of period   152,561    66,295 
           
Cash and cash equivalents at the end of period   155,805    127,979 

 

11

 

 

Debentures Covenants

 

As of June 30, 2021, Sapiens was in compliance with all of its financial covenants under the indenture for the Series B Debentures, based on having achieved the following in its consolidated financial results:

 

Covenant 1

 

Target shareholders’ equity (excluding non-controlling interest): above $120 million.
Actual shareholders’ equity (excluding non-controlling interest) equal to $379 million.

 

Covenant 2

 

Target ratio of net financial indebtedness to net capitalization (in each case, as defined under the indenture for the Company’s Series B Debentures) below 65%.
Actual ratio of net financial indebtedness to net capitalization equal to (24.03)%.

 

Covenant 3

 

Target ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is below 5.5.
Actual ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is equal to (0.92).

 

 

12